We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Cancer Risk Assessed by Circulating Protein Biomarker Panel

By LabMedica International staff writers
Posted on 10 Aug 2018
Print article
Image: A photomicrograph of squamous-cell carcinoma, a type of non-small-cell carcinoma of the lung, from a fine needle aspiration specimen (Photo courtesy of Nephron).
Image: A photomicrograph of squamous-cell carcinoma, a type of non-small-cell carcinoma of the lung, from a fine needle aspiration specimen (Photo courtesy of Nephron).
The question has been asked whether a risk prediction model based on circulating protein biomarkers improve on a traditional risk prediction model for lung cancer and the current USA screening criteria.

Current screening criteria for lung cancer risk assessments often miss a large proportion of cases. It has recently been suggested that a panel of specific circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.

A large international consortium of scientists led by International Agency for Research on Cancer (Lyon, France) collected prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within one year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort. The samples were used to develop a biomarker risk score based on four proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within one year after blood collection and 90 matched controls from two large European population-based cohorts.

In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (age, 57.7 ± 8.7 years; 68.6% men) from the cohorts, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone. With an overall specificity of 0.83, based on the US Preventive Services Task Force (USPSTF) screening criteria, the sensitivity of the integrated risk model was 0.63 compared to 0.43 for the smoking model. Additionally, at an overall sensitivity of 0.41 the integrated risk model yielded a specificity of 0.95 compared with 0.86 for the smoking model, based on the USPSTF screening criteria.

The authors concluded that these improvements in sensitivity and specificity were consistently observed across each evaluated stratum. Their findings also indicated that the improvement in discrimination afforded by the biomarker score is more modest beyond the initial year after blood draw, which suggests that an annual biomarker test may be necessary in a screening program. The study was published on July 12, 2018, in the journal JAMA Oncology.

Related Links:
International Agency for Research on Cancer

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.